<p>（第一财经）12 月 30 日——华东医药的股票在这家主要的中国制药公司表示监管机构已接受其子公司首款针对成年猫的减肥药的市场申请进行审查后上涨。</p>
<p>华东医药 [深交所：000963] 今日收盘上涨 1.3%，报每股 39.06 元人民币（5.59 美元），而深圳市场整体上涨 0.5%。自去年年底以来，该股已上涨 13%。</p>
<p>中美华东制药的申请于 12 月 26 日被中国农业农村部接受审查，申请销售其针对肥胖猫的普利肽注射剂，其位于杭州的母公司昨晚在微信上宣布。</p>
<p>中国的宠物动物数量逐年增长，仅城市家猫的数量去年就超过 7100 万。根据政府关于宠物行业的白皮书，约 28% 的宠物猫被归类为肥胖。肥胖增加了它们患糖尿病、心脏病、呼吸问题和关节问题的风险。</p>
<p>华东医药表示，在一项 III 期临床试验中，肥胖猫在接受推荐剂量的普利肽注射剂六周后，平均体重减轻了 9.3%，其中 72% 的动物体重减轻超过 5%。测试猫对该药物耐受良好，没有出现不良反应。</p>
<p>普利肽注射剂是一种长效双激动剂，靶向胰高血糖素样肽-1 受体和葡萄糖依赖性胰岛素促分泌多肽受体，根据华东医药的说法，其分类与礼来公司的替尔扎肽相同。华东医药表示，中美华东拥有普利肽注射剂的全球知识产权。</p>
<p>华东医药表示，宠物市场在减肥药方面存在很大缺口，并补充说，普利肽注射剂可能成为全球首款针对超重猫的长效 GLP-1 和 GIP 靶向药物。</p>
<p>诺和诺德的塞马鲁肽和替尔扎肽是全球领先的人用 GLP-1 激动剂，但动物减肥药可能成为制药公司下一个重要的业务。</p>
<p>编辑：马丁·卡迪耶夫</p>

华东医药

<p>华东医药的股价上涨 1.3%，达到 39.06 元人民币，此前农业部接受了其猫用减肥药的申请。这种药物是一种肽类注射剂，在临床试验中显示出良好的效果，72% 的肥胖猫体重减轻超过 5%。宠物减肥药市场正在扩大，城市中有相当数量的猫被归类为肥胖。华东医药旨在通过其创新产品填补这一市场空白，该产品针对的特定受体与人类减肥药类似</p>

<p>(Yicai) Dec. 30 -- Huadong Medicine’s shares rose after the major Chinese drugmaker said regulators had accepted for review a marketing application by one of its subsidiaries for its first-in-class weight-loss drug for adult cats.</p>
<div class="lb-trans"><p>（第一财经）12 月 30 日——华东医药的股票在这家主要的中国制药公司表示监管机构已接受其子公司首款针对成年猫的减肥药的市场申请进行审查后上涨。</p>
</div><p>Huadong Medicine [SHE: 000963] closed 1.3 percent higher at CNY39.06 (USD5.59) per share today, compared with a 0.5 percent gain for the broader Shenzhen market. The stock has risen by 13 percent since the end of last year.</p>
<div class="lb-trans"><p>华东医药 [深交所：000963] 今日收盘上涨 1.3%，报每股 39.06 元人民币（5.59 美元），而深圳市场整体上涨 0.5%。自去年年底以来，该股已上涨 13%。</p>
</div><p>Zhongmei Huadong Pharmaceutical’s application to sell its pribopeptide injection for obese cats was accepted for review by China’s Ministry of Agriculture and Rural Affairs on Dec. 26, its Hangzhou-based parent company announced on WeChat late yesterday.</p>
<div class="lb-trans"><p>中美华东制药的申请于 12 月 26 日被中国农业农村部接受审查，申请销售其针对肥胖猫的普利肽注射剂，其位于杭州的母公司昨晚在微信上宣布。</p>
</div><p>China’s pet animal population is growing year by year, with the number of urban domesticated cats alone reaching more than 71 million last year. About 28 percent of pet felines in the country were classified as obese <strong>,</strong> according to a government white paper on the pet industry. Obesity increases their chances of developing diabetes, heart disease, respiratory problems, and joint issues.</p>
<div class="lb-trans"><p>中国的宠物动物数量逐年增长，仅城市家猫的数量去年就超过 7100 万。根据政府关于宠物行业的白皮书，约 28% 的宠物猫被归类为肥胖。肥胖增加了它们患糖尿病、心脏病、呼吸问题和关节问题的风险。</p>
</div><p>Fat cats lost 9.3 percent of their body weight on average after receiving the recommended dose of the pribopeptide injection for six weeks during a phase III clinical trial, with 72 percent of the animals losing more than 5 percent of their weight, Huadong Medicine said. The test cats tolerated the drug well and had no adverse reactions, it added.</p>
<div class="lb-trans"><p>华东医药表示，在一项 III 期临床试验中，肥胖猫在接受推荐剂量的普利肽注射剂六周后，平均体重减轻了 9.3%，其中 72% 的动物体重减轻超过 5%。测试猫对该药物耐受良好，没有出现不良反应。</p>
</div><p>Pribopeptide injection, a long-acting dual agonist targeting the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor, is classified in the same dual-target category as Eli Lilly’s tirzepatide, according to Huadong Medicine. Zhongmei Huadong owns the pribopeptide injection's global intellectual property rights, it added.</p>
<div class="lb-trans"><p>普利肽注射剂是一种长效双激动剂，靶向胰高血糖素样肽-1 受体和葡萄糖依赖性胰岛素促分泌多肽受体，根据华东医药的说法，其分类与礼来公司的替尔扎肽相同。华东医药表示，中美华东拥有普利肽注射剂的全球知识产权。</p>
</div><p>There is a large gap in the pet market for weight loss drugs, Huadong Medicine said, adding that the pribopeptide injection will likely become the world's first long-acting drug targeting GLP-1 and GIP in overweight cats.</p>
<div class="lb-trans"><p>华东医药表示，宠物市场在减肥药方面存在很大缺口，并补充说，普利肽注射剂可能成为全球首款针对超重猫的长效 GLP-1 和 GIP 靶向药物。</p>
</div><p>Novo Nordisk's Semaglutide and tirzepatide are the two leading GLP-1 agonists for humans worldwide, but weight-loss drugs for animals will likely become the next important business for pharmaceutical companies.</p>
<div class="lb-trans"><p>诺和诺德的塞马鲁肽和替尔扎肽是全球领先的人用 GLP-1 激动剂，但动物减肥药可能成为制药公司下一个重要的业务。</p>
</div><p>Editor: Martin Kadiev</p>
<div class="lb-trans"><p>编辑：马丁·卡迪耶夫</p>
</div>

中国的华东医药在其猫用减肥药申请被卫生部接受后股价上涨